Literature DB >> 3509884

Contribution of lipopolysaccharide to pathogenicity of Haemophilus influenzae: comparative virulence of genetically-related strains in rats.

A Zwahlen1, L G Rubin, E R Moxon.   

Abstract

The elaboration of type b capsule plays an important role in determining virulence of Haemophilus influenzae but the contribution of lipopolysaccharide to pathogenicity of this organism remains undefined. Using DNA from a virulent type b H. influenzae donor strain and a capsule-deficient recipient (Rd:01), we constructed capsular transformants having lipopolysaccharide characteristics either similar to (strain Rd/b+:01), or different from (strain Rd/b+:02), the recipient strain. These two type b transformants had similar type b capsule and outer membrane proteins. Comparative virulence studies in rats showed that strain Rd/b+:02 was more virulent than Rd/b+01 as assessed by magnitude of bacteraemia, incidence of meningitis and mortality. Similarly, strain Rd/b-:02 exhibited greater pathogenicity in C3-depleted rats than its genetically-related strain Rd:01. We conclude that lipopolysaccharide composition plays a significant role in mediating the potential of H. influenzae to cause invasive infections. In addition, the findings suggest that there is linkage of virulence genes involved in lipopolysaccharide and capsule expression.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3509884     DOI: 10.1016/0882-4010(86)90008-2

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  29 in total

Review 1.  Challenge of investigating biologically relevant functions of virulence factors in bacterial pathogens.

Authors:  R Moxon; C Tang
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-05-29       Impact factor: 6.237

2.  Nicotinamide ribosyl uptake mutants in Haemophilus influenzae.

Authors:  Mark Herbert; Elizabeta Sauer; Graeme Smethurst; Anita Kraiss; Anna-Karina Hilpert; Joachim Reidl
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

3.  The Haemophilus influenzae Type b hcsA and hcsB gene products facilitate transport of capsular polysaccharide across the outer membrane and are essential for virulence.

Authors:  Soila Sukupolvi-Petty; Susan Grass; Joseph W St Geme
Journal:  J Bacteriol       Date:  2006-06       Impact factor: 3.490

4.  Molecular cloning of the Haemophilus influenzae gmhA (lpcA) gene encoding a phosphoheptose isomerase required for lipooligosaccharide biosynthesis.

Authors:  J S Brooke; M A Valvano
Journal:  J Bacteriol       Date:  1996-06       Impact factor: 3.490

5.  Phase-variable lipopolysaccharide structures enhance the invasive capacity of Haemophilus influenzae.

Authors:  J N Weiser; A Williams; E R Moxon
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

6.  Specific detection of Haemophilus influenzae type b lipooligosaccharide by immunoassay.

Authors:  J Mertsola; R S Munford; O Ramilo; X Sáez-Llorens; M M Mustafa; G H McCracken; E J Hansen
Journal:  J Clin Microbiol       Date:  1990-12       Impact factor: 5.948

7.  Identification of a new locus involved in expression of Haemophilus influenzae type b lipooligosaccharide.

Authors:  G P Jarosik; E J Hansen
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

8.  Decoration of lipopolysaccharide with phosphorylcholine: a phase-variable characteristic of Haemophilus influenzae.

Authors:  J N Weiser; M Shchepetov; S T Chong
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

9.  Role of cerebrospinal fluid pleocytosis and Haemophilus influenzae type b capsule on blood brain barrier permeability during experimental meningitis in the rat.

Authors:  A J Lesse; E R Moxon; A Zwahlen; W M Scheld
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

10.  Interaction of capsulate Haemophilus influenzae with human airway mucosa in vitro.

Authors:  R C Read; A A Rutman; P K Jeffery; V J Lund; A P Brain; E R Moxon; P J Cole; R Wilson
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.